Article | Published:

A combination of astragaloside I, levistilide A and calycosin exerts anti-liver fibrosis effects in vitro and in vivo

Acta Pharmacologica Sinicavolume 39pages14831492 (2018) | Download Citation



Liver fibrosis is excessive accumulation of extracellular matrix proteins that results from various chronic liver diseases. Hepatic stellate cells (HSCs) play an essential role in the pathogenesis of liver fibrosis. Danggui Buxue Tang (DBT) is a classic formula of Chinese traditional medicine. We previously showed that DBT could ameliorate liver fibrosis in rats. However, the bioactive components of DBT in the treatment of liver fibrosis remain unknown. In this study we evaluated 14 ingredients from DBT in human hepatic stellate cell line LX-2, and found that astragaloside I (A), levistilide A (L) and calycosin (C) produced synergistic proliferation inhibition on LX-2 cells and TGF-β1-activated LX-2 cells. Thus, we prepared a mixture of them, and named this combination as ALC formula. Using high-content screening and Western blot assay we revealed that the ALC formula significantly reduced the expression of α-SMA and collagen I in LX-2 cells. The in vivo anti-fibrosis effects of ALC formula were evaluated in a liver fibrosis model in C57BL/6 mice established through injection of dimethylnitrosamine (DMN 2 mg/kg, ip) for 4 weeks. In the third week, the nice were injected with ALC formula (astragaloside I 44.21 mg/kg per day, levistilide A 6 mg/kg per day and calycosin 3.45 mg/kg per day; ip) or sorafenib, a positive control drug (6 mg/kg per day, ip) for 2 weeks. We found that administration of the ALC formula markedly decreased collagen deposition, hydroxyproline (Hyp) content and α-SMA expression levels in the liver tissues compared to the model mice. In conclusion, the present study demonstrates for the first time that astragaloside I, levistilide A and calycosin may be the 3 main bioactive components in DBT; their combination exerts anti-liver fibrosis effects in vitro and in vivo.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut 2015; 64: 830–41.

  2. 2

    Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012; 18: 1028–40.

  3. 3

    Mederacke I, Dapito DH, Affò S, Uchinami H, Schwabe RF. High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. Nat Protocols 2015; 10: 305–15.

  4. 4

    Lee JH, Jang EJ, Seo HL, Ku SK, Lee JR, Shin SS, et al. Sauchinone attenuates liver fibrosis and hepatic stellate cell activation through TGF-β/Smad signaling pathway. Chem Biol Interact 2014; 224: 58–67.

  5. 5

    Zhang L, Schuppan D. Traditional Chinese Medicine (TCM) for fibrotic liver disease: hope and hype. J Hepatol 2014; 61: 166–68.

  6. 6

    Lv J, Zhao Z, Chen Y, Wang Q, Tao Y, Yang L, et al. The chinese herbal decoction danggui buxue tang inhibits angiogenesis in a rat model of liver fibrosis. Evid Based Complement Alternat Med 2012; 224: 58–67.

  7. 7

    Chen Y, Chen Q, Lu J, Li FH, Tao YY, Liu CH. Effects of Danggui Buxue Decoction on lipid peroxidation and MMP-2/9 activities of fibrotic liver in rats. Chin J Integr Med 2009; 15: 435–41.

  8. 8

    Wang WL, Sheu SY, Chen YS, Kao ST, Fu YT, Kuo TF, et al. Evaluating the bone tissue regeneration capability of the Chinese herbal decoction Danggui Buxue Tang from a molecular biology perspective. Biomed Res Int 2014; 2014: 853234.

  9. 9

    Zierau O, Zheng KY, Papke A, Dong TT, Tsim KW, Vollmer G. Functions of Danggui Buxue Tang, a Chinese Herbal Decoction containing Astragali Radix and Angelicae Sinensis Radix, in uterus and liver are both estrogen receptor-dependent and -independent. Evid Based Complement Alternat Med 2014; 2014: 438531.

  10. 10

    Gong AG, Li N, Lau KM, Lee PS, Yan L, Xu ML, et al. Calycosin orchestrates the functions of Danggui Buxue Tang, a Chinese herbal decoction composing of Astragali Radix and Angelica Sinensis Radix: An evaluation by using calycosin-knock out herbal extract. J Ethnopharmacol 2015; 168: 150–7.

  11. 11

    Zhao P, Zhou WC, Li DL, Mo XT, Xu L, Li LC, et al. Total glucosides of Danggui Buxue Tang attenuate BLM-induced pulmonary fibrosis via regulating oxidative stress by inhibiting NOX4. Oxid Med Cell Longev 2015; 2015: 645814.

  12. 12

    Ye TS, Zhang YW, Zhang XM. Protective effects of Danggui Buxue Tang on renal function, renal glomerular mesangium and heparanase expression in rats with streptozotocin-induced diabetes mellitus. Exp Ther Med 2016; 11: 2477–83.

  13. 13

    Yi L, Qi LW, Li P, Ma YH, Luo YJ, Li HY. Simultaneous determination of bioactive constituents in Danggui Buxue Tang for quality control by HPLC coupled with a diode array detector, an evaporative light scattering detector and mass spectrometry. Anal Bioanal Chem 2007; 389: 571–80.

  14. 14

    Zhang WL, Zheng KY, Zhu KY, Zhan JY, Bi CW, Chen JP, et al. Chemical and biological assessment of Angelica herbal decoction: comparison of different preparations during historical applications. Phytomedicine 2012; 19: 1042–8.

  15. 15

    Lin LZ, He XG, Lian LZ, King W, Elliott J. Liquid chromatographic–electrospray mass spectrometric study of the phthalides of Angelica sinensis and chemical changes of Z-ligustilide. J Chromatogr A 1998; 810: 71–9.

  16. 16

    Lao S, Li S, Kan KK, Li P, Wan J, Wang Y, et al. Identification and quantification of 13 components in Angelica sinensis (Danggui) by gas chromatography–mass spectrometry coupled with pressurized liquid extraction. Anal Chim Acta 2004; 526: 131–7.

  17. 17

    Dong TT, Zhao KJ, Gao QT, Ji ZN, Zhu TT, Li J, et al. Chemical and biological assessment of a Chinese herbal decoction containing Radix Astragali and Radix Angelicae Sinensis: determination of drug ratio in having optimized properties. J Agric Food Chem 2006; 54: 2767–74.

  18. 18

    Wang P, Liang YZ. Chemical composition and inhibitory effect on hepatic fibrosis of Danggui Buxue Decoction. Fitoterapia 2010; 81: 793–8.

  19. 19

    Chan PH, Zhang WL, Cheung CY, Tsim KW, Lam H. Quality control of Danggui Buxue Tang, a Traditional Chinese Medicine Decoction, by 1H-NMR metabolic profiling. Evid Based Complement Alternat Med 2014; 2014: 567893.

  20. 20

    Shi X, Tang Y, Zhu H, Li W, Li W, Li Z, et al. Pharmacokinetic comparison of seven major bio-active components in normal and blood deficiency rats after oral administration of Danggui Buxue decoction by UPLC-TQ/MS. J Ethnopharmacol 2014; 153: 169–77.

  21. 21

    Zhang YZ, Xu F, Yi T, Zhang JY, Xu J, Tang YN, et al. Chemical profile analysis and comparison of two versions of the classic TCM formula Danggui Buxue Tang by HPLC-DAD-ESI-IT-TOF-MSn. Molecules 2014; 19: 5650–73.

  22. 22

    Yuan Y, Zong J, Zhou H. Bian Z-Y, Deng W. Dai J, et al. Puerarin attenuates pressure overload-induced cardiac hypertrophy. J Cardiol 2014; 63: 73–81.

  23. 23

    Wang L, Zhou GB, Liu P, Song JH. Liang Y, Yan XJ, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A 2008; 105: 4826–31.

  24. 24

    Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440–6.

  25. 25

    Chou TC. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity—Letter. Cancer Res 2011; 71: 2793–93.

  26. 26

    Eid SY, El-Readi MZ, Wink M. Synergism of three-drug combinations of sanguinarine and other plant secondary metabolites with digitonin and doxorubicin in multi-drug resistant cancer cells. Phytomedicine 2012; 19: 1288–97.

  27. 27

    Jamall IS, Finelli V, Hee SQ. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem 1981; 112: 70–5.

  28. 28

    Gressner A, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76–99.

  29. 29

    Kisseleva T, Brenner DA. Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol 2006; 21 (s3).

  30. 30

    Tsukada S, Parsons CJ, Rippe RA. Mechanism of liver fibrosis. Clin Chim Acta 2006; 364: 33–60.

  31. 31

    Elpek GÖ. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: an update. World J Gastroenterol 2014; 20: 7260.

  32. 32

    Seki E, Brenner DA. Recent advancement of molecular mechanisms of liver fibrosis. J Hepatobiliary Pancreat Sci 2015; 22: 512–8.

  33. 33

    Zhou DJ, Mu D, Jiang MD, Zheng SM, Zhang Y, He S, et al. Hepatoprotective effect of juglone on dimethylnitrosamine-induced liver fibrosis and its effect on hepatic antioxidant defence and the expression levels of α-SMA and collagen III. Mol Med Rep 2015; 12: 4095–102.

  34. 34

    Wang Y, Gao J, Zhang D, Zhang J, Ma J, Jiang H. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 2010; 53: 132–44.

  35. 35

    Thabut D, Routray C, Lomberk G, Shergill U, Glaser K, Huebert R, et al. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology 2011; 54: 573–85.

  36. 36

    Deng YR, Ma HD, Tsuneyama K, Yang W, Wang YH, Lu FT, et al. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib. J Autoimm 2013; 46: 25–34.

  37. 37

    Gao J, Huang Y, Li P, Xu D, Li J, Liu Y, et al. Antifibrosis effects of total glucosides of Danggui–Buxue–Tang in a rat model of bleomycin-induced pulmonary fibrosis. J Ethnopharmacol 2011; 136: 21–6.

  38. 38

    Gao J. Feng Lj, Huang Y, Li P, Xu Dj, Li J, et al. Total glucosides of Danggui Buxue Tang attenuates bleomycin-induced pulmonary fibrosis via inhibition of extracellular matrix remodelling. J Pharm Pharmacol 2012; 64: 811–20.

  39. 39

    Wei MG, Sun W, Xiong PH, Shao JD. Antifibrotic effect of the Chinese herbs Modified Danggui Buxue Decoction on adriamycin-induced nephropathy in rats. Chin J Integr Med 2012; 18: 591–8.

  40. 40

    Huang X, Kong L, Li X, Chen X, Guo M, Zou H. Strategy for analysis and screening of bioactive compounds in traditional Chinese medicines. J Chromatogr B 2004; 812: 71–84.

  41. 41

    Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scandinavian J Gastroenterol 2005; 40: 867–72.

Download references


This work was supported by grants from the National Natural Science Foundation of China (No 81402515 and 81473404).

We thank Dr Jing LYU for providing the methods and other helps.

Author information


  1. Institute of Liver Diseases, Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China

    • Tao Guo
    • , Zu-long Liu
    • , Qiang Zhao
    • , Zhi-min Zhao
    •  & Cheng-hai Liu
  2. Shanghai Clinical Key Laboratory of Traditional Chinese Medicine, Shanghai, 201203, China

    • Zhi-min Zhao
    •  & Cheng-hai Liu
  3. Department of Gastroentology, Hospital No.455 of the PLA, Shanghai, 200052, China

    • Tao Guo


  1. Search for Tao Guo in:

  2. Search for Zu-long Liu in:

  3. Search for Qiang Zhao in:

  4. Search for Zhi-min Zhao in:

  5. Search for Cheng-hai Liu in:

Corresponding authors

Correspondence to Zu-long Liu or Cheng-hai Liu.

About this article

Publication history